Nambi V - Search Results

1

Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future.

Mansoor T, Rao BH, Gupta K, Parikh SS, Abramov D, Mehta A, Al Rifai M, Virani SS, Nambi V, Minhas AMK, Koshy SKG. Mansoor T, et al. Among authors: nambi v. Am J Cardiovasc Drugs. 2024 Dec 20. doi: 10.1007/s40256-024-00712-x. Online ahead of print. Am J Cardiovasc Drugs. 2024. PMID: 39707142 Review.

2

Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure.

Mansoor T, Khalid SN, Bilal MI, Ijaz SH, Fudim M, Greene SJ, Warraich HJ, Nambi V, Virani SS, Fonarow GC, Abramov D, Minhas AMK. Mansoor T, et al. Among authors: nambi v. Am J Cardiovasc Drugs. 2024 Jul;24(4):481-504. doi: 10.1007/s40256-024-00658-0. Epub 2024 Jun 22. Am J Cardiovasc Drugs. 2024. PMID: 38907865 Review.

3

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.

Saeed A, Virani SS, Jones PH, Ballantyne CM, Nambi V. Saeed A, et al. Among authors: nambi v. J Clin Lipidol. 2018 Sep-Oct;12(5):1141-1145. doi: 10.1016/j.jacl.2018.05.017. Epub 2018 Jun 1. J Clin Lipidol. 2018. PMID: 30318064

4

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.

Pickett JK, Shah M, Gillette M, Jones P, Virani S, Ballantyne C, Nambi V. Pickett JK, et al. Among authors: nambi v. JACC Case Rep. 2020 Jun 17;2(7):1042-1045. doi: 10.1016/j.jaccas.2020.04.039. eCollection 2020 Jun 17. JACC Case Rep. 2020. PMID: 34317411 Free PMC article.

5

Ongoing and future clinical trials of device therapies for patients with heart failure.

Khalid SN, Mansoor T, Bilal MI, Ijaz SH, Fudim M, Greene SJ, Nambi V, Virani SS, Fonarow GC, Abramov D, Minhas AMK. Khalid SN, et al. Among authors: nambi v. Curr Probl Cardiol. 2024 Nov;49(11):102805. doi: 10.1016/j.cpcardiol.2024.102805. Epub 2024 Aug 17. Curr Probl Cardiol. 2024. PMID: 39159710 Review.

6

Bempedoic Acid in Secondary Prevention.

Mousavi I, Nambi V, Abushamat LA, Al-Kindi SG, Shapiro MD, Sperling L, Virani SS, Minhas AMK. Mousavi I, et al. Among authors: nambi v. Am J Prev Cardiol. 2024 Aug 6;19:100715. doi: 10.1016/j.ajpc.2024.100715. eCollection 2024 Sep. Am J Prev Cardiol. 2024. PMID: 39224771 Free PMC article.

7

The future of hypertension pharmacotherapy: Ongoing and future clinical trials for hypertension.

Mansoor T, Farrukh F, Khalid SN, Abramov D, Michos ED, Mehta A, Paul TK, Dani SS, Al Rifai M, Misra A, Nambi V, Virani SS, Minhas AMK. Mansoor T, et al. Among authors: nambi v. Curr Probl Cardiol. 2025 Jan;50(1):102922. doi: 10.1016/j.cpcardiol.2024.102922. Epub 2024 Nov 8. Curr Probl Cardiol. 2025. PMID: 39522662 Review.

8

The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Virani SS, Nambi V. Virani SS, et al. Among authors: nambi v. Curr Atheroscler Rep. 2007 Aug;9(2):97-103. doi: 10.1007/s11883-007-0004-9. Curr Atheroscler Rep. 2007. PMID: 17877917 Review.

9

Novel markers of inflammation in atherosclerosis.

Virani SS, Polsani VR, Nambi V. Virani SS, et al. Among authors: nambi v. Curr Atheroscler Rep. 2008 Apr;10(2):164-70. doi: 10.1007/s11883-008-0024-0. Curr Atheroscler Rep. 2008. PMID: 18417072 Review.

10

Lipid management: considerations in acute coronary syndrome.

Polsani VR, Virani SS, Nambi V. Polsani VR, et al. Among authors: nambi v. Curr Cardiol Rep. 2008 Jul;10(4):334-41. doi: 10.1007/s11886-008-0053-x. Curr Cardiol Rep. 2008. PMID: 18611369

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters